Correspondence 0001493152-24-052439 from Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX)

Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: Dec. 30, 2024 · CIK: 0001022899 · Accession: 0001493152-24-052439

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-280244

Date

June 14, 2024

Author

Chief

Form

CORRESP

Company

Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)

Letter

Protagenic Therapeutics, Inc.

Fifth Avenue

New York, NY 10010

December 30, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

Re: Protagenic Therapeutics, Inc.

Registration Statement on Form S-3

Filed June 14, 2024

File No. 333-280244

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence with EDGAR on December 20, 2024, in which we, Protagenic Therapeutics, Inc., requested to accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-280244) (the “Registration Statement”) so that it would become effective on December 24, 2024 at 12:00 pm, Eastern Standard Time, or as soon as practicable thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.

Very
truly yours,
PROTAGENIC
THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

Protagenic
Therapeutics, Inc.

149
Fifth Avenue

New
York, NY 10010

December
30, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    Re:
    Protagenic
    Therapeutics, Inc.

    Registration
    Statement on Form S-3

    Filed
    June 14, 2024

    File
    No. 333-280244

Ladies
and Gentlemen:

Reference
is made to our letter, filed as correspondence with EDGAR on December 20, 2024, in which we, Protagenic Therapeutics, Inc., requested
to accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-280244) (the “Registration
Statement”) so that it would become effective on December 24, 2024 at 12:00 pm, Eastern Standard Time, or as soon as practicable
thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally
withdraw our request for acceleration of the effective date.

    Very
    truly yours,

    PROTAGENIC
    THERAPEUTICS, INC.

    By:
    /s/
    Alexander K. Arrow

    Alexander
    K. Arrow

    Chief
    Financial Officer

cc:
Dean Colucci, Duane Morris LLP

SecProbe.io